How Does Serotonin Affect Your Eyes?

Serotonin influences nearly every part of the eye, from the tear film on the surface to the retinal neurons in the back. The eye is not just a passive recipient of serotonin circulating in the bloodstream; multiple eye tissues produce their own serotonin receptors and use this chemical messenger for local signaling. For most people, the most noticeable connection between serotonin and vision comes through medications that alter serotonin levels, particularly antidepressants, which can trigger dry eyes, dilated pupils, and in rare cases more serious complications like acute glaucoma or accelerated cataract development.

Serotonin Receptors Live Throughout the Eye

Serotonin does not just arrive at the eye through the bloodstream and hope for the best. Eye tissues actively express a range of serotonin receptor subtypes, which means the eye is equipped to respond to serotonin in specific, targeted ways. Research on human ciliary body tissue, the structure behind the iris that produces the fluid filling the front of the eye, found receptors for at least five serotonin subtypes: 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7.¹ The conjunctiva, the thin membrane covering the white of the eye and lining the eyelids, also carries serotonin receptors. In human conjunctival tissue, researchers detected 5-HT1D, 5-HT1F, and 5-HT7 subtypes, with the 5-HT7 receptor appearing to be the most prominent based on antibody staining.²

The retina at the back of the eye has its own serotonin system too. A specialized group of retinal cells called amacrine cells produce serotonin and form connections with retinal ganglion cells, the neurons responsible for sending visual information to the brain. About half of retinal ganglion cells respond when exposed to a serotonin 2C receptor activator.³ All of this means serotonin is not an outsider to the eye. It is woven into the signaling architecture of multiple ocular tissues, which explains why drugs that change serotonin levels can produce such varied eye-related effects.

Serotonin and Pupil Size

Your pupils constantly adjust in size based on light conditions, emotional state, and cognitive effort. Serotonin plays a role in this process, though it works alongside other neurotransmitters rather than controlling pupil size on its own. In a mouse study, directly stimulating serotonin-producing neurons in the brainstem caused pupils to dilate by a median of about 8%, an effect that lingered for several seconds after the stimulation ended.⁴ The degree of dilation varied depending on context: when the environment was more predictable, serotonin bursts had a larger pupil-dilating effect than when conditions were more uncertain. This suggests serotonin’s influence on the pupil is tied to how the brain processes surprise and expectation, not just a simple on-off switch for dilation.

The connection between serotonin and pupil dilation becomes clinically relevant in two situations. First, drugs that flood the brain with serotonin can cause noticeable pupil widening. MDMA, for instance, dilates pupils through a combination of serotonin and norepinephrine activity.⁵ Second, in serotonin syndrome, a dangerous condition caused by excessive serotonin activity, dilated pupils are a hallmark sign. A case report documented a patient with serotonin syndrome presenting with pupils fixed at 6 millimeters, which is well above normal resting size, along with tremors and exaggerated reflexes.⁶ Clinicians actually used pupil measurements to track this patient’s response to treatment, showing how directly pupil size reflects serotonin activity.

Why Antidepressants Cause Dry Eyes

Dry eye is one of the most common eye complaints among people taking SSRIs and similar antidepressants, and the mechanism is not as simple as you might expect. Older antidepressants like tricyclics were known to dry out the eyes through their anticholinergic effects, basically blocking the nerve signals that stimulate tear production. SSRIs were supposed to be cleaner in this regard, but the dry eye problem persists anyway. A study comparing antidepressant users to controls found that patients on SSRIs had significantly lower tear production as measured by the Schirmer test, with wetting measurements at or below 5 millimeters, compared to those on serotonin-norepinephrine reuptake inhibitors. The researchers specifically noted that since most SSRIs lack anticholinergic properties, the dryness likely involves a different mechanism tied to serotonin itself.⁷

The picture across studies is not perfectly uniform. Another study found that about 41% of SSRI users had dry eye compared to 17% of controls, a statistically significant difference. For SNRI users, however, the rate was about 22%, which was not significantly different from controls.⁸ Given that the conjunctiva has its own serotonin receptors, one plausible explanation is that increased serotonin signaling at the ocular surface disrupts the normal regulation of tears and mucus production. The effect does not seem to depend on how long you have been taking the medication, which suggests it kicks in relatively early in treatment.

If you are on an SSRI and notice your eyes feeling gritty or tired, this is worth mentioning to your prescriber. Artificial tears can help manage symptoms, and the dryness does not typically cause lasting damage. But for people who already have borderline dry eye or who wear contact lenses, the added strain from an SSRI can push comfort past its threshold.

The Acute Glaucoma Question

Acute angle-closure glaucoma happens when the drainage angle between the iris and cornea suddenly narrows or closes, causing a rapid, painful spike in eye pressure. Because SSRIs can mildly dilate the pupil, there has been concern that they could trigger this condition in susceptible people. The evidence supports the concern, but it’s important to keep the absolute risk in perspective. A study found that starting an SSRI was associated with a nearly six-fold increase in the odds of acute angle-closure glaucoma within the first week of use. Higher doses carried even greater risk, with an odds ratio above eight. Fluoxetine and sertraline were the most frequently prescribed SSRIs among the affected patients.⁹

Those numbers sound alarming, but the same study noted that fewer than 1% of all acute angle-closure cases were linked to new SSRI use. Acute angle-closure glaucoma is itself uncommon, and it overwhelmingly affects people with specific anatomical risk factors, particularly those with narrow drainage angles, which is more common in people who are farsighted, older, or of East Asian descent. If you have been told you have narrow angles, mentioning it before starting an SSRI is worth doing. For the vast majority of people starting antidepressants, this is not a realistic danger. The risk also appears to be highest in the first days of treatment and does not persist with ongoing use.

Cataracts and Long-Term SSRI Use

A more subtle but potentially more widespread concern is the link between serotonin-modifying drugs and cataract development. The lens of the eye contains serotonin transporters, and laboratory research has shown that serotonin can accumulate in lens tissue. Over time, this accumulation may contribute to the protein changes that cloud the lens. A systematic review and meta-analysis pooling data from multiple studies found that SSRI use was associated with a modest increase in cataract risk, with combined odds roughly 12% higher than in non-users. SNRIs and tricyclic antidepressants showed similar small increases.¹⁰

A population-based study looking specifically at cataract surgery found a somewhat larger effect with prolonged use. People who had taken SSRIs for a year or more had about a 36% higher chance of undergoing cataract surgery, with the risk especially pronounced for citalopram, which carried a 53% increase.¹¹ These are relative risk increases applied to a condition that already becomes common with aging, so the absolute added risk for any individual is modest. But for someone weighing antidepressant options over the long term, particularly an older adult who may already be developing early lens changes, it is one more factor to discuss with a doctor.

Serotonin’s Role in the Retina’s Internal Clock

The retina does not just detect light and send signals to the brain. It has its own internal clock, and serotonin is directly involved in running it. Inside the retina, serotonin serves as the raw material from which melatonin is made. Enzymes in retinal cells convert serotonin to melatonin through a two-step process, and the activity of the key enzyme in this pathway follows a strong day-night cycle. At night, the enzyme’s activity and melatonin levels spike dramatically. In chick retinas, for example, the nighttime peak is roughly 15 times higher than daytime levels.¹²

This local melatonin production is thought to work in tandem with dopamine to regulate processes in the retina that follow circadian rhythms, such as the sensitivity of photoreceptors and how the retina adapts between daytime and nighttime vision.¹³ More recent work has confirmed that retinal melatonin levels can be regulated at multiple points in this metabolic pathway, including the initial availability of serotonin itself, the activity of the converting enzyme, and a degradation step that breaks melatonin down within the retina.¹⁴ This means serotonin availability in the retina doesn’t just affect how you process images; it feeds directly into the clock that tunes retinal function to the time of day.

Visual Hallucinations and Psychedelic Drugs

Psychedelic drugs like psilocybin and LSD produce vivid visual hallucinations primarily by activating serotonin 2A receptors in the brain’s visual processing areas. The hallucinations, geometric patterns, color shifts, and complex imagery with eyes closed, are not generated at the eye itself but result from disrupted signaling in the cortex. Specifically, activating 5-HT2A receptors appears to push the brain into a state where spontaneous neuronal firing overwhelms the processing of actual visual input. Researchers found that psilocybin reduced a specific brain response to visual stimuli, the N170 potential, and suggested that this reduction is a key mechanism behind why the brain starts “seeing” things that aren’t there.¹⁵

Brain imaging work has added detail to this picture. Under psilocybin, both early visual areas and higher visual-association regions showed increased self-inhibition, meaning they became less responsive to incoming signals. At the same time, the normal top-down inhibition from higher brain areas to lower visual areas was reduced, essentially loosening the brain’s usual control over what the visual system reports.¹⁶ The result is that internal brain activity starts to dominate perception. You are not hallucinating because your eyes are sending wrong signals. You are hallucinating because your brain’s visual cortex, flooded with serotonin 2A receptor activity, is generating its own content and ignoring what the eyes are actually seeing.

Serotonin and Eye Growth in Myopia

One of the more surprising areas of serotonin and eye research involves nearsightedness. Myopia develops when the eyeball grows too long from front to back, causing distant objects to focus in front of the retina instead of on it. Atropine eye drops are one of the most studied treatments for slowing myopia progression in children, and recent work suggests serotonin signaling is part of how atropine works. Researchers found that blocking serotonin receptors pharmacologically could inhibit the development of experimental myopia in a dose-dependent fashion, meaning higher doses produced a stronger anti-growth effect.¹⁷ This is still early-stage research, but it opens the possibility that serotonin receptor drugs could eventually join the toolkit for managing childhood myopia, a condition that is becoming more common worldwide.

The connection between serotonin and eye growth also shows up in development. In zebrafish embryos, blocking serotonin 2 receptor signaling caused abnormally small eyes, a condition called microphthalmia, along with reduced expression of genes important for retinal development. The affected gene, pax6a, is a critical regulator of how retinal neurons form and organize.¹⁸ Zebrafish are not humans, but pax6 is one of the most highly conserved eye-development genes across vertebrates, so disrupting it through serotonin pathway interference hints at a deep evolutionary role for serotonin in building the eye.

Protecting Retinal Ganglion Cells in Glaucoma

Glaucoma damages the retinal ganglion cells, the neurons that carry visual information from the eye to the brain. Once these cells die, the vision loss is permanent. There is growing interest in whether serotonin receptor activation could help protect these cells. In a rat model of chronic glaucoma, elevated eye pressure reduced the expression of serotonin 1A receptors in the retina and led to significant ganglion cell death. Treating the animals with a serotonin 1A receptor activator improved ganglion cell survival. The protective mechanism appeared to involve adjusting the balance of inhibitory signaling within the retina, reducing excessive GABA release that was suppressing ganglion cell function.¹⁹

Separately, work on how the serotonin 2C receptor affects retinal ganglion cells found that this receptor normally restrains the growth of ganglion cell neurites, the branching projections neurons use to communicate. Mice lacking the 2C receptor had ganglion cells that grew longer neurites and showed amplified electrical responses to visual patterns.³ Neither of these findings has translated into a treatment for human glaucoma yet, but the research collectively suggests that serotonin receptors in the retina are doing more than relaying signals. They are actively regulating the health and wiring of the cells most vulnerable to glaucoma damage.

Serotonin as a Corneal Trophic Factor

The cornea, the transparent front surface of the eye, is one of the most densely innervated tissues in the body. Those nerves do more than detect pain and trigger blinking. They release chemical signals that help maintain and renew the corneal surface. Serotonin is one of several nerve-derived trophic factors involved in this process, alongside substance P, calcitonin gene-related peptide, and others.²⁰ When corneal nerves are damaged, whether by surgery, infection, or conditions like diabetes, the loss of these trophic signals can lead to persistent epithelial defects and poor wound healing, a condition called neurotrophic keratopathy. The role of serotonin in corneal maintenance is less studied than some of the other nerve-derived factors, but its presence in the signaling mix means that disruptions to serotonin levels could theoretically contribute to corneal surface problems, particularly in people whose corneal nerve supply is already compromised.

Migraine Drugs, Serotonin, and Retinal Blood Vessels

Triptans, the go-to medication class for acute migraine attacks, work by activating serotonin 1B and 1D receptors to constrict dilated blood vessels. Because the retina has a delicate blood supply, there has been longstanding concern about whether repeated triptan use could increase the risk of retinal vascular occlusion, a blockage that can cause sudden vision loss. A large population-based cohort study examined this question in migraine patients and found that triptan use did not significantly reduce or increase the risk of retinal vascular occlusion compared to untreated migraine.²¹ The same neutral result held for ergotamine, another serotonin-active migraine drug. Migraine itself carries a modestly elevated risk of retinal vascular events, but the serotonin-targeting treatments used to manage it do not appear to make things worse. For migraine sufferers who worry about their eyes every time they reach for a triptan, this is reassuring data.